Name:
Date:
ISCORE
CNS
GCS
Ischemic Stroke Predictive Risk Score
Calculator
clear
Check if you need help to estimate stroke severity (CNS)

Manual CNS/NHISS entry

CNS NIHSS

ISCORE

Age
years
Sex Male Female
Stroke Severity
CNS
Stroke Subtype

Risk Factors

Atrial fibrillation
CHF
Previous myocardial infarction
Current smoker

Comorbid Conditions

Cancer
Renal disease on dialysis

Preadmission Disability

Dependent

Glucose on Admission

≥7.5 mmol/L (>135 mg%)
Outcomes: Mortality

30 Day Mortality

ISCORE
Mortality
%

1 Year Mortality

ISCORE
Mortality
%
Functional Outcomes at Discharge

30 Day Death or Disability

ISCORE
Death or Disability
%

30 Day Death or Institutionalization

ISCORE
Death or Institutionalization
%
Death was captured up to 30-days post-discharge
Thrombolytic Therapy
Probability of Good Clinical Outcome (mRS 0-2)
tPA therapy
Complications of Intracranial Hemorrhage
Information

Click here to download the original paper for the IScore

The early use of prognostic data using simple elements may help clinicians in making treatment decisions and in providing reliable information when counseling patients and their families.

The IScore (Ischemic Stroke Predictive Risk Score) is a validated tool that may assist clinicians to estimate the risk of death (at 30-day and at 1-year), disability (as defined by the modified Rankin scale >=3) and institutionalization, during the initial assessment in the Emergency department or early after hospital admission for patients with an acute ischemic stroke.

It consist in clinical parameters and chronic comorbid conditions: including age, sex, stroke severity and subtype, history of atrial fibrillation, coronary artery disease, cardiac cancer, kidney disease on dialysis, smoking, hyperglycemia on admission, and dependency prior to the stroke, all associated with 30-day and 1-year mortality. The score was validated in an internal and external cohorts including over 16,000 patients with an acute ischemic stroke.

IScore allows the input of stroke severity either using the CNS scale (as validated) or the NIHSS (commonly used in the initial assessment by stroke neurologists). Patients with decreased level of consciousness, i.e. coma, should be given a CNS = 0 or NIHSS >= 23.

The score assigned to each variable is shown in the right upper corner of this website. Just simple select the characteristics of your patient and you will have the estimated risk of death displayed right away.

View the NIH Stroke Scale.

Thrombolytic Therapy

Thrombolysis is the most accepted effective and proven treatment for an acute ischemic stroke. The decision of giving intravenous thrombolysis (tPA) may be challenging, especially in patients with higher prevalence comorbid conditions, pre-admission dependency, and dementia. Patients and families wonder about the likelihood of a good outcome, especially if the risk of developing hemorrhagic complications is high. Unfortunately, there are no tools that assist clinicians predict the response to tPA.

We recently developed and validated a risk score (iScore) that can be used to estimate the risk of death and disability after an acute ischemic stroke (Saposnik et al. Circulation 2011 and Stroke 2011). The iScore was designed to allow for broader utility at academic centers or small community hospitals with limited resources. It includes clinical variables easily obtained in the early hours of hospital presentation.

In the present study, we applied the iScore (www.sorcan.ca/iscore) to over 12,000 patients with an acute ischemic stroke admitted to 11 stroke centers in Ontario. A cohort of patients with stroke treated at 154 general hospitals in Ontario was used to determine the consistency of our results.

Among patients with a low and medium iScore, tPA use was associated with reduction in death and disability. However, there was no such benefit in patients with a higher iScore. Moreover, the risk of neurological deterioration and intracerebral hemorrhage was significantly higher in this high risk group.

Patients with a high iScores may not have a clinically meaningful benefit from tPA (NNT 385; NS) while carrying a significantly higher risk of hemorrhagic complications (NNH 5-17; p<0.05)

Results were consistent in the validation cohort, as well as, when applying the iScore to data derived from the NINDS tPA randomized clinical trial (manuscript in preparation).

The risk, benefits, and quality of life after tPA in selected high risk groups has been under debate. Our study suggests that the iScore can be used to estimate the clinical response and risk of complications after thrombolytic therapy for ischemic stroke. These results may facilitate information to clinicians when discussing therapeutic options and prognosis with patients and their families.

Definitions

NNH: number needed to harm
mRS 0-2: modified ranking scale 0-2 for a favorable outcome

References
Saposnik G, Fang J, Kapral M, Tu J, Mamdani M, Austin P, Johnston S, on behalf of the Investigators of the Registry of the Canadian Stroke Network (RCSN) and the Stroke Outcomes Research Canada (SORCan) Working Group. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke February 2012.
Saposnik G, Kapral MK, Liu Y, O'Donnell M, Raptis R, Tu J, Mamdani M, Austin PC, on behalf of the Investigators of the Registry of the Canadian Stroke Network and the Stroke Outcome Research Canada (SORCan) Group. IScore: A Risk Score to Predict Death early after Hospitalization for an Acute Ischemic Stroke. Circulation February 2011.
Saposnik G, Raptis R, Kapral MK, Liu Y, Tu JV, Mamdani M, Austin PA, on behalf of the Investigators of the Registry of the Canadian Stroke Network and the Stroke Outcome Research Canada (SORCan) Working Group. The IScore Predicts Poor Functional Outcomes Early After Hospitalization for an Acute Ischemic Stroke. Stroke December 2011.
Nilanont Y, Komoltri C, Saposnik G, et al. The Canadian Neurological Scale and the NIHSS: development and validation of a simple conversion model. Cerebrovasc Dis. 2010;30(2):120-6.
The Canadian Neurological Scale: validation and reliability assessment. Côté R, Battista RN, Wolfson C, Boucher J, Adam J, Hachinski V. Neurology. 1989 May;39(5):638-43.
Disclaimer

Terms of Use

By using this website, you are agreeing to these terms of use. If you do not agree to all of these terms of use, do not use this site. SORCan may revise and update these terms without notice at any time. Your continued use of this site means that you accept those changes. You are not permitted to change these terms of use.

The SORCan is located in Toronto, Ontario, Canada. These terms of use are an Ontario contract.

No Medical Advice

The information on this website is provided for informational purposes only. It is not a substitute for professional medical advice, diagnosis or treatment. Moreover, the calculators listed on this website are not meant to be a substitute for professional advice or to provide clinical guidance, and are not to be used for medical diagnosis or treatment. All calculations must be confirmed and validated in the appropriate cohorts before clinical use or diagnostic purposes by qualified medical professionals.

If you have or suspect you have a health problem, please consult your physician. If you have or suspect you are experiencing a health emergency, please promptly visit a hospital emergency department in your area. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

This site contains health-related and medical-related materials that may be explicit. If you find these materials offensive, you may not want to use our site.

If you rely on any information appearing on or provided in relation to this site, you do so solely at your own risk.

Disclaimers

SORCan, Dr. Gustavo Saposnik, and the developers (Dr. Chi-Ming Chow and Edward Brawer) make no representations as to any matter whatsoever, including accuracy, fitness for a particular purpose or non-infringement.

Any websites linked from this website are created by other organizations. Those organizations are responsible for the information contained within their sites. Even when this website refers or links to another website, SORCan does not endorse the content on any other organization’s website. SORCan, Dr. Gustavo Saposnik, and the developers (Dr. Chi-Ming Chow and Edward Brawer) do not control and are not responsible for the content of those websites or any advertisements on those websites. Your use of those other websites is at your own risk and subject to the terms of use for those sites.

We do not operate, control, supply, or endorse any information, products, services or merchandise that is not clearly identified as supplied by SORCan. We do not represent that files available for downloading will be free from any code that contains contaminating or destructive properties, including infections, viruses, worms or Trojan horses.

Limitation of Liability

The site and the content provided are on an "as is" basis. When using the site, information will be transmitted over a medium that is beyond the control and jurisdiction of SORCan, Dr. Gustavo Saposnik, and the developers (Dr. Chi-Ming Chow and Edward Brawer). SORCan, Dr. Gustavo Saposnik, or the developers (Dr. Chi-Ming Chow and Edward Brawer) assume no liability for or relating to the delay, failure, interruption or corruption of any data or other information transmitted in connection with use of this site.

SORCan, Dr. Gustavo Saposnik, and the developers (Dr. Chi-Ming Chow and Edward Brawer) are not liable to you or anyone else for any decision made or action taken based on reliance upon the information contained on or provided through this website. The use of the information shall be at your own risk. The sole and exclusive remedy for dissatisfaction with this site is to stop using this site.

Indemnity

You shall indemnify SORCan, its officer, directors, employees, agents, licensors, content providers and contractors for any claims, liabilities, harms and losses (including reasonable legal and accounting fees) resulting from or related to your violation of these terms of use.

Author
Dr. Gustavo Saposnik

Developers
Dr. Chi-Ming Chow
Edward Brawer

Available on the iPhone App Store

Powered by USquareSoft

Copyright © 2010-2012 SORCan. All Rights Reserved.